Ascletis drug cuts psoriasis severity by 48.9 per cent
September 29, 2026 | 15:56
Biopharmaceutical firm Ascletis achieved a 48.9 per cent placebo-adjusted reduction in psoriasis severity scores during a 28-day clinical trial of its oral inhibitor ASC50 in the United States.
Mobile Version